临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2014年
11期
896-899
,共4页
特发性肺纤维化%依达拉奉%血氧分压%TGF-β1
特髮性肺纖維化%依達拉奉%血氧分壓%TGF-β1
특발성폐섬유화%의체랍봉%혈양분압%TGF-β1
Idiopathicpulmonaryfibrosis%Edaravone%Bloodoxygenpartialpressure%TGF-beta1
目的：探讨依达拉奉治疗特发性肺纤维化的临床效果及安全性。方法将2010年6月至2013年6月就诊的85例特发性肺纤维化患者作为研究对象。采用随机分组法分为对照组（一般常规治疗组）42例和治疗组（对照组治疗基础上加依达拉奉组）43例。对两组患者的血氧分压、通气量、血清外源性转移生长因子-β1（ TGI-β1）及一氧化碳弥散量和临床疗效进行比较。结果治疗前后比较，两组患者的血氧分压及一氧化碳弥散量都明显升高，但治疗组的升高程度更大（ P <0.01）。治疗组患者血清TGF-β1及通气量情况的改善均较对照组明显（ P <0.05）。两组均表现为血清TGF-β1下降，通气量升高。两组疗效比较，治疗组的总有效率高于对照组（ P <0.05）。两组患者不良反应经比较差异无差异性（ P >0.05）。结论特发性肺纤维化在常规治疗的基础上联用依达拉奉，能获得较好的临床疗效，且具有良好的安全性，值得临床推广应用。
目的：探討依達拉奉治療特髮性肺纖維化的臨床效果及安全性。方法將2010年6月至2013年6月就診的85例特髮性肺纖維化患者作為研究對象。採用隨機分組法分為對照組（一般常規治療組）42例和治療組（對照組治療基礎上加依達拉奉組）43例。對兩組患者的血氧分壓、通氣量、血清外源性轉移生長因子-β1（ TGI-β1）及一氧化碳瀰散量和臨床療效進行比較。結果治療前後比較，兩組患者的血氧分壓及一氧化碳瀰散量都明顯升高，但治療組的升高程度更大（ P <0.01）。治療組患者血清TGF-β1及通氣量情況的改善均較對照組明顯（ P <0.05）。兩組均錶現為血清TGF-β1下降，通氣量升高。兩組療效比較，治療組的總有效率高于對照組（ P <0.05）。兩組患者不良反應經比較差異無差異性（ P >0.05）。結論特髮性肺纖維化在常規治療的基礎上聯用依達拉奉，能穫得較好的臨床療效，且具有良好的安全性，值得臨床推廣應用。
목적：탐토의체랍봉치료특발성폐섬유화적림상효과급안전성。방법장2010년6월지2013년6월취진적85례특발성폐섬유화환자작위연구대상。채용수궤분조법분위대조조（일반상규치료조）42례화치료조（대조조치료기출상가의체랍봉조）43례。대량조환자적혈양분압、통기량、혈청외원성전이생장인자-β1（ TGI-β1）급일양화탄미산량화림상료효진행비교。결과치료전후비교，량조환자적혈양분압급일양화탄미산량도명현승고，단치료조적승고정도경대（ P <0.01）。치료조환자혈청TGF-β1급통기량정황적개선균교대조조명현（ P <0.05）。량조균표현위혈청TGF-β1하강，통기량승고。량조료효비교，치료조적총유효솔고우대조조（ P <0.05）。량조환자불량반응경비교차이무차이성（ P >0.05）。결론특발성폐섬유화재상규치료적기출상련용의체랍봉，능획득교호적림상료효，차구유량호적안전성，치득림상추엄응용。
Objective ToexploretheclinicalefficacyandsafetyofEdaravoneintreatmentofidiopathicpulmonaryfibrosis.Methods Atotalof85patientswithidiopathicpulmonaryfibrosisduringJune2010toJune2013wereallocatedinthisstudy,theywererandomlydividedin-to control group( conventional treatment group,n=42 cases)and trial group( conventional treatment plus Edaravone,n=43 cases). The blood oxygen partial pressure,amount of ventilation,serum level of TGI-beta 1 and amount of carbon monoxide diffusion were examined and compared betweenthese2groupsinordertodeterminethecurativeeffectofpatientsinthesetwogroups.Results Thebloodoxygenpartialpressureanda-mount of carbon monoxide diffusion in patients of these 2 groups were significantly increased compared with those before treatment,but the degree of increase in trial group was bigger than that of control group,and the difference was significant( P <0. 01). The improvement in serum level of TGF-beta 1 and ventilation condition in patients of trial group was more significant than those of patients in control group,and the difference was statistically significant( P <0. 05). The serum level of TGF-beta 1 was dropped,and ventilation was increased in patients of these 2 groups. The curative effect and total effective rate of patients in trial group were higher than those of patients in control group,and the difference was statis-tically significant( P <0. 05). There was no difference in occurrence of adverse reactions between patients of two groups( P >0. 05). Conclu-sion Onthebasisofconventionaltreatment,theapplicationofEdaravoneintreatmentofpatientswithidiopathicpulmonaryfibrosiscanachieve good clinical curative effect with good safety,it is worthy to be clinically popularized and applied.
